Twitxy Saved

Prashanth L Kukkle

Verified account This account is verified. Learn more

@prashanthlk

Neurologist | Expert in Parkinson’s & Movement Disorders | IPMDS - MDS AOS | Founding Member MovementDisordersIndia | GP2 Parkinson Genetics | Bangalore, India
Bengaluru, India Joined December 2009
235 Following 1.4K Followers 509 Posts

Latest posts 5

Prashanth L Kukkle Verified account @prashanthlk
Which emerging Parkinson’s therapies could change care soon—and which are still on the horizon?

Prof Lorraine Kalia’s (@kalialabs ) #IAPRDCongress talk offered a clear, grounded map. Continuous subcutaneous levodopa may help people with poorly controlled fluctuations. Cell-based therapy, α-synuclein immunotherapy and gene transfer open exciting possibilities, but much of this work remains investigational.

The practical questions matter as much as the science: Who might benefit? What can we offer now? When should we refer someone to a trial or consider genetic testing?

The challenges are real: getting treatments to the right place in the brain, targeting the right form of α-synuclein, and helping transplanted cells survive and function.
From infusion therapies to gene replacement, silencing and editing, the field is moving in many directions. The next step is matching each approach to the right person, with evidence and care.
@PRDAssociation
0 replies 1 reposts 13 likes 370 views View on X
Prashanth L Kukkle Verified account @prashanthlk
“Is it—or is it not—Parkinson’s disease?”
Prof. @kailashbhatia made this a live question at #IAPRDCongress, exploring diagnosis from different angles: the clinical picture, smell and reported body-odour changes, α-synuclein biomarkers, diagnostic criteria, and genetic clues such as PLA2G6-related parkinsonism.
A striking contrast: loss of smell is familiar in Parkinson’s—but could a characteristic body odour offer another clue? And how should we weigh emerging biomarkers against the clinical examination, especially in early or atypical cases?
His four-case challenge brought the central message home: no single sign or test tells the whole story. Diagnosis comes from putting the evidence together—and staying curious.
@PRDAssociation
0 replies 2 reposts 10 likes 562 views View on X
Prashanth L Kukkle Verified account @prashanthlk
Where does Parkinson’s disease begin—and what happens to α-synuclein along the way?
At #IAPRDCongress, @touteiro talk, based on his review with Eduardo Tolosa, explored brain-first and periphery-first ideas, including possible gut and olfactory routes.
One especially thought-provoking question: is disease driven by toxic α-synuclein buildup (#synucleinopathy ), loss of its normal function (#synucleinopenia ), or some combination of both?
The talk also highlighted that Lewy bodies contain more than α-synuclein, and that their structure may matter for understanding cell-specific toxicity and developing PET ligands or therapeutic antibodies. The proposed gut–nose–brain neuroimmune connection adds another intriguing piece to the puzzle.
Perhaps the question is not only where does #Parkinson’s begin? but also what changes first, and in which cells?
Prashanth L Kukkle Verified account @prashanthlk
A warm opening to the 31st #IAPRDCongress in #Milan .
The day began by celebrating two remarkable contributions to our field. José A. Obeso’s Melvin Yahr lecture explored focal motor onset in Parkinson’s disease, raising a fascinating question: what might its asymmetry tell us about how the disease begins? Beomseok Jeon’s Lifetime Achievement lecture turned to tissue biomarkers and what they may reveal about Parkinson’s biology.
Then Congress Chair @AlbertoAlbanes5 brought Milan’s history—and its contribution to neurology—into the story. Emanuela Biscotti followed with a glimpse of Leonardo da Vinci’s Milan.
A lovely meeting of science, history and place to begin the congress. What better setting for asking new questions about Parkinson’s disease?